FDA Grants Designation to Investigational Drug for Head and Neck Most cancers

The U.S. Meals and Drug Administration (FDA) has granted quick monitor designation to an investigational drug generally known as CRB-701, doubtlessly providing a brand new choice to sufferers with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), in line with a information launch from Corbus Prescribed drugs Holdings, Inc.

This designation applies to sufferers whose most cancers has progressed after receiving platinum-based chemotherapy and an anti-PD(L)-1 remedy. Importantly, that is the second quick monitor designation the FDA has given to CRB-701, because it beforehand granted one for relapsed or refractory metastatic cervical most cancers in 2024.

CRB-701 is a next-generation antibody-drug conjugate (ADC) that particularly targets a protein known as Nectin-4, which is often present in sure cancers. It makes use of a cleavable linker and a managed drug-to-antibody ratio, designed to ship chemotherapy on to most cancers cells whereas limiting injury to wholesome tissue. In accordance with the information launch, the quick monitor program goals to hurry the event and evaluate of remedies for severe ailments the place an unmet medical want exists, which suggests CRB-701 might attain sufferers extra shortly if future research verify its profit.

Understanding the CRB-701 Scientific Trial

CRB-701 is at present being studied in an ongoing section 1/2 trial for sufferers with superior stable tumors that specific Nectin-4. The trial is designed to guage security, pharmacokinetics (how the drug strikes via the physique) and efficacy. Researchers first offered early dose escalation information earlier this yr, and new findings on dose optimization can be shared on the European Society for Medical Oncology (ESMO) Congress in October 2025.

The examine has three components, in line with data on the trial from clinicaltrials.gov. The primary (Half A) checks escalating doses of CRB-701 to find out the utmost tolerated dose. The second (Half B) goals to establish the advisable section 2 dose (RP2D), each as a single agent and together with an anti-PD-1 remedy. The third stage (Half C) will then increase testing in a number of most cancers sorts utilizing the established optimum dose. Sufferers enrolled obtain CRB-701 via an intravenous infusion and endure scans, blood checks and different assessments to measure how the drug impacts their tumors.

To take part, sufferers should have superior or metastatic stable tumors recognized to precise Nectin-4 and should have progressed after not less than one prior remedy. Sure situations, comparable to uncontrolled central nervous system metastases, important cardiovascular points or extreme neuropathy, can exclude sufferers from the examine.

Head and Neck Most cancers: What Sufferers Ought to Know

Head and neck most cancers is a broad class that features a number of cancers beginning in areas such because the mouth, throat, voice field, nasal cavity and associated constructions, in line with the Cleveland Clinic. Most are squamous cell carcinomas, which start within the skinny, moist lining of those areas. Therapy sometimes focuses on controlling the most cancers whereas preserving important capabilities like speech, swallowing and facial motion. Detecting and treating the illness early considerably improves the possibilities of a remedy.

Particular subtypes of head and neck cancers embrace oral most cancers, salivary gland most cancers, nasal and sinus cancers, and cancers of the throat, tonsils and larynx. Within the U.S., charges of tobacco-related head and neck cancers are declining, however HPV-related circumstances are rising, particularly in folks below age 50. Globally, head and neck cancers signify roughly 4.5% of all most cancers diagnoses.

With quick monitor designation and notable early examine outcomes, CRB-701 represents a possible new choice for sufferers dealing with difficult-to-treat head and neck cancers, in line with the information launch. Further trial information anticipated later this yr will present extra perception into the drug’s security and effectiveness.

References

1. “FDA Grants Quick Observe Designation to Corbus Prescribed drugs’ Nectin-4 Focusing on ADC CRB-701 in Head and Neck Squamous Cell Carcinoma,” by Corbus Prescribed drugs Holdings, Inc. Information launch; Sept. 16, 2025.
2. “A Part 1/2 Research to Examine CRB-701 in Strong Tumors.” clinicaltrials.gov. https://www.clinicaltrials.gov/examine/NCT06265727
3. “Head and Neck Most cancers,” by Cleveland Clinic. https://my.clevelandclinic.org/well being/ailments/14458-head-and-neck-cancer

For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.